[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100415933":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":17,"locations":22,"responsibleParty":41,"collaborators":43,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":7,"enrollmentInfo":73,"targetDuration":76,"studyType":77,"phases":7,"briefSummary":78,"conditions":79,"keywords":7,"overallStatus":25,"whyStopped":7,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"University Hospital, Caen","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"occurence of atrial fibrillation","all adult patients with an active cancer and experiencing atrial fibrillation will be consecutively include. Active cancers will be defined according Agnelli et al. (NEJM 2020; 382:1599-1607).",[13],{"name":14,"affiliation":15,"role":16},"Joachim Alexandre, MD, PhD","Caen Normandy University Hospital, France","PRINCIPAL_INVESTIGATOR",[18],{"name":14,"role":19,"phone":20,"phoneExt":7,"email":21},"CONTACT","+330231064770","alexandre-j@chu-caen.fr",[23],{"facility":24,"status":25,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Alexandre","RECRUITING","Caen","Normandy","14000","France","FR",{"type":32,"coordinates":33},"Point",[34,35],-0.35912,49.18585,{"lat":35,"lon":34},[38,40],{"name":39,"role":19,"phone":7,"phoneExt":7,"email":7},"Joachim ALEXANDRE, MD, PhD",{"name":7,"role":19,"phone":7,"phoneExt":7,"email":21},{"type":42,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[44,47,49,51,53,55,57,59,61],{"name":45,"class":46},"University Hospital, Marseille, France","UNKNOWN",{"name":48,"class":46},"Hospices Civils de Lyon, France",{"name":50,"class":46},"Centre Francois Baclesse, Caen, France",{"name":52,"class":46},"University Hospital of Saint-Etienne, France",{"name":54,"class":46},"Hôpital Lariboisière Fernand Widal, Paris, France",{"name":56,"class":46},"Institut de Cancérologie de l'Ouest Nantes, France",{"name":58,"class":46},"Fundacion Cardio Onco, Santiago, Chile",{"name":60,"class":6},"University of Newcastle, Australia",{"name":62,"class":6},"University Hospital, Rouen","100415933","atrial-fibrillation-in-active-cancer-patients-100415933",false,"NCT04696081","Atrial Fibrillation in Active Cancer Patients","Multicenter International Prospective Registry to Identify Major Cardiovascular Events Associated With the Occurrence of Atrial Fibrillation in Active Cancer Patients","AFIB-CANCER","Inclusion Criteria:\n\n* adult patients\n* outpatients or hospitalized patients\n* with a confirmed cancer (other than basal-cell or squamous-cell carcinoma of the skin, primary brain tumor, known intracerebral metastases, or acute leukemia) and an active cancer (defined as cancer that had been diagnosed within the past 6 months or recurrent locally advanced or metastatic cancer, for which anticancer treatment was being given at the time of enrollment or during 6 months before enrollment)\n* at least 1 episode of atrial fibrillation (new onset AF occuring after cancer diagnosis or history of paroxysmal of persistant AF prior to cancer diagnosis and an AF recurrence after cancer diagnosis)\n* in sinus rhythm at the time of cancer diagnosis\n\nExclusion Criteria:\n\n* patient with palliative cares or other conditions resulting in short term death (death expected in the month following atrial fibrillation occurrence)\n* history of long-standing persistant or permanent AF prior to cancer diagnosis","ALL","18 Years",{"count":74,"type":75},1000,"ESTIMATED","2 Years","OBSERVATIONAL","Atrial fibrillation is a common complication of both cancer and anticancer drugs but the consequences of such events remain poorly known and are not adressed in both phase III oncological trials and cardiological guidelines. The objective of this study is to create a prospective multicenter international registry of adult patients with an active cancer and experiencing atrial fibrillation to study major cardiovascular events occurrence during a 1 year follow-up.",[80,81,82,83],"Cancer","Drug Toxicity","Atrial Fibrillation","Cardiovascular Complication","2024-08-08",{"date":86,"type":87},"2024-08-09","ACTUAL",{"date":89,"type":87},"2021-09-01",{"date":91,"type":75},"2026-01-01",{"name":5,"class":6},1]